NSE · Healthcare · Biotechnology
EPS came in at 2.99 against a street estimate of 9.30 — a miss of 67.8%.
with an average price target of ₹940.00.
MIXED Q1 FY'27 revenue grew 31% YoY to ₹190cr but EBITDA fell 8% due to water scarcity (₹35cr sales deferred) and solar subsidy costs. Management confirms ₹1,000cr FY'27 target remains on track; margins to recover in Q2. Ambernath facility progressing toward EU audit. Q1 FY'27 Management expects Europe to remain largest market long-term due to product portfolio fit and CMO/CDMO opportunity concentration. Analysts pressed on Patalganga timeline delay, solar subsidy permanence, customs/compliance risk, and growth ceiling. Management clarified construction begun, costs temporary and pass-through enabled, incident isolated, and internal systems upgrades underway to support >20% growth if regulatory approvals accelerate. 2026-08-14…
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 SUPRIYA LIFESCIENCE LIMITED – FINANCIAL SUMMARY FY 2025-26 HEADLINE NUMBERS • Revenue from Operations: ₹8,278.75 million (FY2025: ₹6,964.85 million) | 2026-09-01 |
| Q1 FY27 earnings call SUPRIYA LIFESCIENCE LIMITED – Q1 FY'27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue Q1 FY'27: Rs. 190 crores (31% YoY growth vs Rs. 145 crores in Q1 | 2026-08-18 |
| Quarterly results · Q1 FY27 SUPRIYA LIFESCIENCE LTD. - Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue: Rs 189.75 crore in Q1 FY27, up 30.8% year-over-year from Rs 145.07 | 2026-08-13 |
| Investor presentation · Q1 FY27 SUPRIYA LIFESCIENCE LIMITED - Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue Q1 FY27: INR 1,897.5 Mn, up 31% YoY (Q1 FY26: INR 1,450.7 Mn) • EB | 2026-08-13 |
| Q4 FY26 earnings call SUPRIYA LIFESCIENCE LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 277 crores (vs INR 184 crores in Q4 FY25), growth of 50% year- | 2026-06-02 |
| Quarterly results · Q4 FY26 SUPRIYA LIFESCIENCE LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: Rs 276.53 crore, up 50.2% YoY from Rs 184.11 crore in Q4 FY25 • | 2026-05-28 |
| Investor presentation · Q4 FY26 SUPRIYA LIFESCIENCE LIMITED – Q4 FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue FY26: INR 8,278.7 Mn (up 18.9% YoY from INR 6,964.8 Mn | 2026-05-27 |
| Quarterly results · Q3 FY26 SUPRIYA LIFESCIENCE LIMITED – DOCUMENT SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company operates in a single business segment: Pharmaceuticals • Lis | 2026-03-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1 / share ex-date Sep 4, 2026 | 2026-09-04 |
| Dividend | ₹1 / share ex-date Sep 4, 2025 · record Sep 5, 2025 | 2025-09-04 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Supriya Lifescience Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.